Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04432857
Title AN0025 and Pembrolizumab Combination in Advanced Solid Tumors
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Adlai Nortye Biopharma Co., Ltd.

triple-receptor negative breast cancer

lung squamous cell carcinoma

bladder urothelial carcinoma

colorectal cancer

cervical cancer

lung non-squamous non-small cell carcinoma


E7046 + Pembrolizumab

Age Groups: senior | adult
Covered Countries USA | FRA

No variant requirements are available.